4-(3-nitrobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one | 590408-00-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-nitrobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one
• 英文别名: 4-[(3-nitrophenyl)methyl]-5,6,7,8-tetrahydro-2H-phthalazin-1-one
• CAS: 590408-00-7
• 化学式: C₁₅H₁₅N₃O₃
• 分子量: 285.302
• InChiKey: CVZABBLCLPXSSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-nitrobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 4-(3-aminobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one
  参考文献：
  名称：

  [EN] PHTHALAZINONE DERIVATIVES
  [FR] DÉRIVÉS DE PHTALAZINONE

  摘要：

  式（I）的化合物：其中RH代表融合环己烯环上的一个或多个可选取代基；R1从H和卤素中选择；RN从H和可选取代的C1-10烷基中选择；RC1和RC2分别从H、R、C(=O)OR中选择，其中R为可选取代的C1-10烷基、可选取代的C5-20芳基或可选取代的C3-20杂环烷基；RC1和RC2与它们连接的碳原子一起可以形成一个可选取代的螺联的C5-7碳环或杂环。

  公开号：

  WO2009034326A1
• 作为产物：
  描述：

  3-(3-nitro-benzylidene)-4,5,6,7-tetrahydro-3H-isobenzofuran-1-one 在 肼 作用下， 以 水 为溶剂， 反应 16.0h， 生成 4-(3-nitrobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one
  参考文献：
  名称：

  [EN] PHTHALAZINONE DERIVATIVES
  [FR] DÉRIVÉS DE PHTALAZINONE

  摘要：

  式（I）的化合物：其中RH代表融合环己烯环上的一个或多个可选取代基；R1从H和卤素中选择；RN从H和可选取代的C1-10烷基中选择；RC1和RC2分别从H、R、C(=O)OR中选择，其中R为可选取代的C1-10烷基、可选取代的C5-20芳基或可选取代的C3-20杂环烷基；RC1和RC2与它们连接的碳原子一起可以形成一个可选取代的螺联的C5-7碳环或杂环。

  公开号：

  WO2009034326A1

文献信息

• Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Seko Takuya

  公开号：US20050085476A1

  公开（公告）日：2005-04-21

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  公式(I)所代表的融合吡啶嗪衍生物或其药学上可接受的盐（其中每个符号的含义如说明书所定义）。由于抑制多聚腺苷酸核苷酸聚合酶，公式（I）所代表的化合物可用作各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等处）、炎症性疾病（炎症性肠病、多发性硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等）、糖尿病、休克、头部创伤、肾功能衰竭、高痛感等的预防和/或治疗剂。此外，这些化合物可用作抗逆转录病毒剂（HIV等）、癌症治疗敏感剂和免疫抑制剂。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• PHTHALAZINONE DERIVATIVES
  申请人：JAVAID Muhammad Hashim

  公开号：US20090186897A1

  公开（公告）日：2009-07-23

  A compound of the formula (I): wherein R H represents one or more optional substituents on the fused cyclohexene ring; R 1 is selected from H and halo; R N is selected from H and optionally substituted C 1-10 alkyl; and R C1 and R C2 are independently selected from H, R, C(═O)OR, where R is optionally substituted C 1-10 alkyl, optionally substituted C 5-20 aryl or optionally substituted C 3-20 heterocyclyl; R C1 and R C2 together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C 5-7 carbocylic or heterocyclic ring.

  式(I)的化合物：其中RH表示融合的环己烯环上一个或多个可选取代基；R1选自H和卤素；RN选自H和可选取代的C1-10烷基；RC1和RC2独立地选自H、R、C(═O)OR，其中R是可选取代的C1-10烷基、可选取代的C5-20芳基或可选取代的C3-20杂环烷基；RC1和RC2连同它们所连接的碳原子可以形成可选取代的螺合C5-7环烷基或杂环烷基。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1477175A1

  公开（公告）日：2004-11-17

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  由式（I）代表的融合哒嗪衍生物或其药学上可接受的盐（其中各符号的含义如说明书中所定义）。 由于能抑制多（ADP-核糖）聚合酶，式（I）代表的化合物可作为各种缺血性疾病（脑、脊髓、心脏、消化道、骨骼肌、视网膜等）、炎症性疾病（炎症性肠病）的预防和/或治疗药物。炎症性疾病（炎症性肠病、多发性脑硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌肉萎缩症、腰椎管狭窄症等）、糖尿病、休克、头部创伤、肾功能衰竭、痛觉减退等。此外，这些化合物还可用作抗逆转录病毒（HIV 等）的药物、治疗癌症的增敏剂和免疫抑制剂。
• Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2281818A1

  公开（公告）日：2011-02-09

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式 (I) 所代表的融合哒嗪衍生物或其药学上可接受的盐（其中各符号的含义如说明书中所定义）。 由于能抑制多（ADP-核糖）聚合酶，式（I）代表的化合物可作为各种缺血性疾病（脑、脊髓、心脏、消化道、骨骼肌、视网膜等）、炎症性疾病（炎症性肠病）的预防和/或治疗药物。炎症性疾病（炎症性肠病、多发性脑硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌肉萎缩症、腰椎管狭窄症等）、糖尿病、休克、头部创伤、肾功能衰竭、痛觉减退等。此外，这些化合物还可用作抗逆转录病毒（HIV 等）的药物、治疗癌症的增敏剂和免疫抑制剂。